venture debt market is about $800M/year Cash-burning R&D-stage biotechs have big appetites for cash, which is typically addressed with an equity-based diet. It’s also supported through corporate partnerships and other less dilutive means such as grants and foundation funding. But another important and often under-appreciated source of capital are the debt markets – taking a loan out to provide working capital for further R&D.
[...]
How big is the venture debt market in the life sciences? It’s bigger than most people think. Industry insiders have suggested to me that the debt market in the life sciences is about 10% of the equity market: since $7.7B was raised for Life Sciences (Biotech plus Med Tech) in the US alone in 2011, according to PWC Moneytree, that implies the venture debt market is about $800M per year in life sciences alone.
https://lifescivc.com/2012/07/venture-debt-under-appreciated-tool-for-building-biotechs/
How close endo is from full recruitment for urocidin clinical trial?
on the insane side apart of BNC sp, now there is a generic for actos, pioglizatone. the market for urocidin is suddenly getting bigger. Watson, remember them, will make the generic version.
the last stats from UK
- In 2009, 10,540 people in the UK were diagnosed with bladder cancer.
- In 2010 there were 4,907 deaths from bladder cancer in the UK.
- In 2005-2009, 58% of men and 50% of women in England survived their bladder cancer for five years or more.
https://www.cancerresearchuk.org/cancer-info/cancerstats/types/bladder/
let's see what the other Rae has to say and if endo recognize that they have urocidin in clinical trial because i did not like the passage from "Next year 2013 will be our year" to " the next 5 year will be particulary important".
cpt